Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea

JCI Insight

Volumn 2, Issue 6, 2017, Pages

  Vernet, Marie Astrid ^a   Reynard, Stéphanie ^b,c   Fizet, Alexandra ^b,c   Schaeffer, Justine ^b,c   Pannetier, Delphine ^d   Guedj, Jeremie ^d,e   Rives, Max ^f   Georges, Nadia ^f   Garcia Bonnet, Nathalie ^f   Sylla, Aboubacar I ^g   Grovogui, Péma ^g   Kerherve, Jean Yves ^f   Savio, Christophe ^f   Savio Coste, Sylvie ^f   de Séverac, Marie Laure ^f   Zloczewski, Philippe ^f   Linares, Sandrine ^f   Harouna, Souley ^h   M'Lebing Abdoul, Bing ^h   Petitjean, Frederic ^h   Samake, Nenefing ^h   Shepherd, Susan ^h   Kinda, Moumouni ^h   Koundouno, Fara Roger ^h   Joxe, Ludovic ^h   Mateo, Mathieu ^b,c   Lecine, Patrick ⁱ   Page, Audrey ^b,c   Tchamdja, Tang Maleki ^f   Schoenhals, Matthieu ^a   Barbe, Solenne ^h   Simon, Bernard ^j   Tran Minh, Tuan ^j   Longuet, Christophe ^k   L'Hériteau, François ^l   Baize, Sylvain ^b,c   more..

^a CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^b Institut Pasteur   (France)

^c UNIVERSITÉ DE LYON   (France)

^d INSERM   (France)

^e BICHAT HOSPITAL   (France)

^f MINISTÈRE DE LA SANTÉ   (France)

^g MINISTÈRE DE LA SANTÉ   (Guinea)

^h Alliance for International Medical Action   (France)

ⁱ BIOASTER   (France)

^j National à la Croix Rouge Française   (France)

^k Fondation Merieux   (France)

^l CCLIN Paris Nord   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85031108026     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/JCI.INSIGHT.88864     Document Type: Article

References (39)

1. Baize S, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014;371(15):1418-1425.
2. Baize S. Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus. Curr Opin Virol. 2015;10:70-76.
3. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196 Suppl 2:S364-S371.
4. Cournac JM, et al. Rhabdomyolysis in Ebola Virus Disease. Results of an Observational Study in a Treatment Center in Guinea. Clin Infect Dis. 2016;62(1):19-23.
5. Hunt L, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15(11):1292-1299.
6. Schibler M, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis. 2015;15(9):1034-1040.
7. Lyon GM, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371(25):2402-2409.
8. Schieffelin JS, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371(22):2092-2100.
9. WHO Ebola Response Team. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481-1495.
10. Bah EI, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372(1):40-47.
11. Millington OR, Di Lorenzo C, Phillips RS, Garside P, Brewer JM. Suppression of adaptive immunity to heterologous antigens during Plasmodium infection through hemozoin-induced failure of dendritic cell function. J Biol. 2006;5(2):5.
12. Gignoux E, et al. Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. N Engl J Med. 2016;374(1):23-32.
13. Takahashi S, et al. Reduced vaccination and the risk of measles and other childhood infections post-Ebola. Science. 2015;347(6227):1240-1242.
14. Walker PG, White MT, Griffin JT, Reynolds A, Ferguson NM, Ghani AC. Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis. Lancet Infect Dis. 2015;15(7):825-832.
15. Plucinski MM, et al. Effect of the Ebola-virus-disease epidemic on malaria case management in Guinea, 2014: a cross-sectional survey of health facilities. Lancet Infect Dis. 2015;15(9):1017-1023.
16. Barry M, et al. Clinical predictors of mortality in patients with Ebola virus disease. Clin Infect Dis. 2015;60(12):1821-1824.
17. Rosenke K, et al. Plasmodium parasitemia associated with increased survival in Ebola virus-infected patients. Clin Infect Dis. 2016;63(8):1026-1033.
18. Li J, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis. 2016;42:34-39.
19. Lado M, et al. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis. 2015;15(9):1024-1033.
20. Sissoko D, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016;13(3):e1001967.
21. Lanini S, et al. Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest. 2015;125(12):4692-4698.
22. Sow MS, et al. New evidence of long-lasting persistence of Ebola virus genetic material in semen of survivors. J Infect Dis. 2016;214(10):1475-1476.
23. Deen GF, et al. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Preliminary Report [published online ahead of print October 14, 2015]. N Engl J Med. https://doi.org/10.1056/NEJMoa1511410.
24. Mate SE, et al. Molecular evidence of sexual transmission of Ebola virus. N Engl J Med. 2015;373(25):2448-2454.
25. Ksiazek TG, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179 Suppl 1:S177-S187.
26. Wolf T, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428-1435.
27. Uyeki TM, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016;374(7):636-646.
28. Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008;19(8):568-574.
29. Holt SG, Moore KP. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med. 2001;27(5):803-811.
30. Baize S, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol. 2002;128(1):163-168.
31. Leroy EM, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355(9222):2210-2215.
32. Villinger F, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis. 1999;179 Suppl 1:S188-S191.
33. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196 Suppl 2:S357-S363.
34. Baize S, et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol. 2009;83(11):5890-5903.
35. Cressman DE, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274(5291):1379-1383.
36. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. 2004;10(4):201-222.
37. Maruo N, Morita I, Shirao M, Murota S. IL-6 increases endothelial permeability in vitro. Endocrinology. 1992;131(2):710-714.
38. Agarwal N, Pitchumoni CS. Acute pancreatitis: a multisystem disease. Gastroenterologist. 1993;1(2):115-128.
39. Kreuels B, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371(25):2394-2401.